Personalized Immunology in Cancer: Paving the Way Towards a Better Quality of Life

Publish Year: 1399
نوع سند: مقاله ژورنالی
زبان: English
View: 245

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_MCIJO-5-1_002

تاریخ نمایه سازی: 15 بهمن 1399

Abstract:

Conventionally, in specific diseases, patients receive similar therapies; relying on a "one size fits all" approach. The discovery of P5 (Predictive, Preventive, Personalized, Participatory, and psycho-cognitive) improves personalized diagnosis, treatment, and prognosis. Considering the high prevalence, mortality rate, and complexity of cancers, there is a critical necessity to choose specific and individualized therapies in each case. In this point of view, immunology has a vital role in the biological variability of the patient-to-patient system and tumor microenvironment heterogeneity. Thus, it is required to improve personalized immunology in various diseases and cancers as well. Notably, personalized immunology will develop personalized cancer treatments and improve clinical outcomes. In this study, we proposed to review the essential roles of personalized immunology in cancer personalized therapies. Also, we can suggest the transformation of P5 medicine into P6 medicine, with the sixth P standing for personalized immunology.

Authors

Abdolreza Esmaeilzadeh

Cancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Science, Zanjan, Iran

Elnaz Khosh

School of Medicine, Zanjan University of Medical Science, Zanjan, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • 1. Chung KF. Personalised medicine in asthma: time for ac- ...
  • 2. Auffray C, Charron D, Hood L. Predictive, preventive, personalized and ...
  • 3. Gorini A, Pravettoni G. P5 medicine: a plus for a ...
  • 4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, ...
  • 5. Hood L. Systems biology and p4 medicine: past, present, and ...
  • 6. Hood L, Friend SH. Predictive, personalized, preventive, participatory ...
  • 7. Flores M, Glusman G, Brogaard K, Price ND, Hood L. ...
  • 8. Sobradillo P, Pozo F, Agusti A. P4 medicine: the future ...
  • 9. Ziegelstein RC. Personomics: The missing link in the evo- lution ...
  • 10. Mathur L, Ballinger M, Utharala R, Merten CA. Micro- fluidics ...
  • 11. Braig Z. Personalized medicine: From diagnostic to adap- tive. Biomed ...
  • 12. Gorshkov K, Chen CZ, Marshall RE, Mihatov N, Choi Y, ...
  • 13. Esmaeilzadeh A, Farshbaf A. Novel approaches based on autologous stem ...
  • 14. Esmaeilzadeh A, Farshbaf A, Erfanmanesh M. Autolo- gous Hematopoietic ...
  • 15. Hutter G, Nowak D, Mossner M, Ganepola S, Müßig A, ...
  • 16. Gupta RK, Peppa D, Hill AL, Gálvez C, Salgado M, ...
  • 17. Delhalle S, Bode SF, Balling R, Ollert M, He FQ. ...
  • 18. Canonica GW, Ferrando M, Baiardini I, Puggioni F, Racca F, ...
  • 19. Litman T. Personalized medicine—concepts, technologies, and applications in inflammatory skin ...
  • 20. Mandal R, Chan TA. Personalized oncology meets immu- nology: the ...
  • 21. Finotello F, Eduati F. Multi-omics profiling of the tumor microenvironment: ...
  • 22. Navin NE. The first five years of single-cell cancer genom- ...
  • 23. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, ...
  • 24. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, ...
  • 25. Kakimi K, Karasaki T, Matsushita H, Sugie T. Advances in ...
  • 26. Jacob M, Lopata AL, Dasouki M, Abdel Rahman AM. Me- ...
  • 27. Mastelic-Gavillet B, Balint K, Boudousquie C, Gan- non ...
  • 28. Guo Y, Lei K, Tang L. Neoantigen vaccine delivery ...
  • 29. Apostolopoulos V. Cancer Vaccines: Research and Appli- cations. Cancers (Basel). ...
  • 30. Samuel M, Gabrielsson S. Personalized medicine and back–allogeneic exosomes ...
  • 31. Srivastava PK. Immunotherapy of human cancer: les- sons from mice. ...
  • 32. Elahi R, Khosh E, Tahmasebi S, Esmaeilzadeh A. Im- mune ...
  • 33. Esmaeilzadeh A, Tahmasebi S, Athari SS. Chimeric anti- gen receptor-T ...
  • 34. Tahmasebi S, Elahi R, Esmaeilzadeh A. Solid tumors chal- lenges ...
  • 35. Tahmasebi S, Elahi R, Khosh E, Esmaeilzadeh A. Program- mable ...
  • 36. Li J, Wang D, Wang Y. IBI: Identification of Biomark- ...
  • 37. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, ...
  • 38. Steinberg W. The clinical utility of the CA 19-9 tumor-as- ...
  • 39. Holdenrieder S, Pagliaro L, Morgenstern ...
  • 40. Ichiki AT, Krauss S, Israelsen KL, Sonoda T, Collmann R. ...
  • 41. Hagenbeek A, Gadeberg O, Johnson P, Møller Pedersen L, Walewski ...
  • 42. Coombes KR, Morris JS, Hu J, Edmonson SR, Baggerly KA. ...
  • 43. Selleck MJ, Senthil M, Wall NR. ...
  • 44. Liu L, So AY-L, Fan J-B. Analysis of cancer ...
  • 45. Suwinski P, Ong C, Ling MH, Poh YM, Khan AM, ...
  • 46. Tannock IF, Hickman JA. Limits to personalized cancer medicine. N ...
  • نمایش کامل مراجع